Silencing of PRR11 suppresses cell proliferation and induces autophagy in NSCLC cells

Publication date: June 2018Source: Genes &Diseases, Volume 5, Issue 2Author(s): Lian Zhang, Yunlong Lei, Ying Zhang, Yi Li, Youquan Bu, Fangzhou Song, Chundong ZhangAbstractOur previous studies have demonstrated that proline-rich protein 11 (PRR11) is a novel tumor-related gene and implicates in regulating the proliferation in lung cancer. However, its precise role in cell cycle progression remains unclear. Our recent evidences show that PRR11 silencing has an effect on autophagy in non-small-cell lung cancer (NSCLC) cells. Two human NSCLC cell lines, H1299 and A549 were transiently transfected with against PRR11 siRNA. The Cell Counting Kit-8 and plate clone formation assay showed that downregulation of PRR11 inhibited the cell proliferation associated with cell cycle related genes reduced. And our data suggested that PRR11 depletion expression enhanced the autophagosomes formation, followed with downregulation of P62 and upregulation of LC3-II protein. Furthermore, the immunoblotting results indicated that silencing of PRR11 inactivated the Akt/mTOR signaling pathway. Collectively, these results demonstrated PRR11 had an effective role in autophagy in NSCLC cells through Akt/mTOR autophagy signaling pathways. Therefore, it is helpful to clarify the function of PRR11 in tumorigenesis of NSCLC.
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research

Related Links:

In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Our meta-analysis suggested that miR-21 may function as an unfavorable biomarker of prognosis in NSCLC patients. PMID: 30024605 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: We demonstrated that miR-550a-3p regulated the progression of NSCLC cells through TIMP2. Thus, miR-550a-3p axis could serve as a potential therapeutic target for NSCLC treatment. PMID: 30024604 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: Jiang M, Lu HY, Shan XH, Xu W, Geng XD, Lu C, Chen JH Abstract OBJECTIVE: We aimed at exploring the feasibility of noninvasive late arterial phase enhanced CT imaging in evaluating tumor angiogenesis, ischemic necrosis, and glucose metabolism, thereby providing pathological information for the comprehensive treatment plan in non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: 52 cases of NSCLC were enrolled in this study. The mean ischemia necrosis CT quantitative value (INCTQ) and CT enhanced value (CTe) of the tumor were determined, and the immunohistochemical staining of factors relating to tu...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: Propofol inhibits viability and induces apoptosis of A549 cells via an ERK1/2-dependent PUMA signaling. PMID: 30024623 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
ConclusionsWe were unable to predict lung cancer recurrence using a risk-prediction model based on five well-known clinical risk-factors and several biomarkers. Further research should consider novel predictors of recurrence in order to stratify patients with completely resected early-stage NSCLC according to their risk of recurrence.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
AbstractPurpose of ReviewLiquid biopsies have potential as tools for diagnosis, prognosis, and prediction of response to therapy. Herein, we will extensively review four liquid biosources, tumor-educated platelets (TEPs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) and we will clarify their optimal application in non-small cell lung cancer (NSCLC) diagnosis and therapy.Recent FindingsLiquid biopsies are a minimally invasive alternative to tissue biopsies —especially important in NSCLC patients—since tumor tissue is often unavailable or insufficient for complete geneti...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
AbstractAlectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advancedALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with advancedALK-positive NSCLC previously treated with crizotinib. In the USA, alectinib is indicated for the treatment of adults withALK-positive metastatic NSCLC. The recommended dosage for alectinib in the EU and USA is 600  mg twice daily. Well-designed phase III studies in patients withALK-positive NSCLC showed th...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose and therapeutic response are intimately linked, we explored the metabolic differences between isogenic erlotinib-sensitive and -resistant NSCLC cell lines. We discovered that the growth of erlotinib-resistant cells is more sensitive to glucose deprivation.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
AbstractBackgroundNon-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. The major challenge in the treatment of NSCLC patients is intrinsic or acquired resistance to chemotherapy. Molecular markers predicting the outcome of the patients are urgently needed.MethodsHere, we employed patient-derived xenografts (PDXs) to detect predictive methylation biomarkers for platin-based therapies. We used MeDIP-Seq to generate genome-wide DNA methylation profiles of 22 PDXs, their parental ...
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study